Vir Biotechnology, Inc. Number of Reportable Segments
Vir Biotechnology, Inc. (VIR) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:NumberOfReportableSegments · last filed 2026-08-05
- Vir Biotechnology, Inc. number of reportable segments for fiscal 2024 was 1.00 Segment.
Segment
| Period end | Number of Reportable Segments 12 month |
|---|---|
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-02-27 |
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-23 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |